Business Context and Reporting Period
This Form 8-K Current Report was filed by Champions Oncology, Inc. (Nasdaq: CSBR) on March 24, 2026. The filing primarily addresses corporate governance changes regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
- Board Resignation: Dr. Philip Breitfeld resigned from the Board of Directors effective March 24, 2026. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Board Appointment: Dr. Brian Alexander was appointed as a director to fill the vacancy created by Dr. Breitfeld's resignation.
- Related Party Transactions: No reportable related party transactions or material plans/contracts involving Dr. Alexander were disclosed.
Outlook, Risks, and Management Commentary
Management Commentary: The Company highlighted Dr. Alexander's extensive background, including his current role as CEO of Valo Health Inc. and CEO-Partner at Flagship Pioneering. His prior experience includes Senior Vice President for R&D at Roche/Genentech and CEO of Foundation Medicine. He also holds academic and clinical credentials from Harvard Medical School and the Dana-Farber Cancer Institute.
Risks and Contingencies: No specific risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Confirm the effective date of Dr. Breitfeld's resignation and Dr. Alexander's appointment (March 24, 2026).
- Verify Dr. Alexander's current affiliations with Valo Health Inc. and Flagship Pioneering to assess potential conflicts of interest or strategic alignment.
- Review the referenced Press Release (Exhibit 99.1) dated March 30, 2026, for additional context on the leadership transition.
- Note that this filing contains no financial data; investors should refer to the most recent 10-K or 10-Q for financial performance.